Cost-effectiveness Analysis of Centrally Purchased and Original Cefoperazone-Sulbactam Sodium in the Treatment of Patients with Bacterial Infection
Objective:The effectiveness,safety and economy of centrally purchased and original cefoperazone-sulbactam sodium in the treatment of patients with bacterial infections were compared and evaluated based on the cost-effectiveness analysis method,to provide a reference for more rational allocation of medical resources clinically.Methods:Using 191 patients with bacterial infections who were treated with centrally purchased and original cefoperazone-sulbactam sodium in Suqian First Hospital from January to December 2022 as the research objects,the 1:1 nearest neighbor matching method was used to perform propensity score matching,and the effectiveness,safety and economy of centrally purchased and original cefoperazone-sulbactam sodium in the treatment of patients with bacterial infections were compared.Results:After propensity score matching,110 effective cases were finally included,including 55 cases in each of the centrally purchase group and the original group.The clinical effective rates in the centrally purchase group and the original group were 69.09%and 70.91%respectively,the bacterial clearance rates were 58.18%and 60.00%respectively,and the incidences of adverse drug reactions were 5.45%and 3.64%respectively.There was no statistical significance for difference in the three indicators by comparison between the two groups(P＞0.05).Pharmacoeconomic analysis showed that the per capita treatment costs of the centrally purchase group and the original group were RMB 67 804.11 and RMB 5 193.52 respectively,and the cost-effectiveness ratios(CER)were 981.39 and 1 060.56 respectively.The obtained incremental cost-effectiveness ratio(ICER)of the original cefoperazone-sulbactam sodium was 4 060.11.The sensitivity analysis showed that when the cost was reduced by 10%,the incremental cost required for each patient to benefit clinically was RMB 3 654.10 in the original group;when the effect was reduced by 10%,the incremental cost required for each patient to benefit clinically was RMB 4 505.74 in the original group.Conclusion:The effectiveness and safety of centrally purchased cefoperazone-sulbactam sodium and original cefoperazone-sulbactam sodium in the treatment of patients with bacterial infections were similar,but the centrally purchased cefoperazone-sulbactam sodium is significantly more economical.
万方数据
维普
